Shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA – Get Free Report) have been given a consensus recommendation of “Buy” by the fifteen research firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $213.85.
PVLA has been the topic of several research analyst reports. Chardan Capital reissued a “buy” rating and issued a $240.00 price objective on shares of Palvella Therapeutics in a report on Wednesday, October 28th. HC Wainwright started coverage on Palvella Therapeutics in a research report on Friday, November 6th. They set a “strong-buy” rating for the company. Canaccord Genuity Group increased their price objective on Palvella Therapeutics from $232.00 to $243.00 and gave the company a “buy” rating in a research note on Monday, November 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Palvella Therapeutics in a report on Friday, September 25th. Finally, William Blair started coverage on Palvella Therapeutics in a report on Friday, October 16th. They issued an “outperform” rating on the stock.
Check Out Our Latest Report on Palvella Therapeutics
Palvella Therapeutics Stock Down 0.5%
Shares of Palvella Therapeutics stock traded down $0.70 on Friday, reaching $152.48. 240,297 shares of the stock were exchanged, compared to its average volume of 281,191. Palvella Therapeutics has a twelve month low of $72.22 and a twelve month high of $179.95. The firm has a market capitalization of $2.23 billion, a price-to-earnings ratio of -27.72 and a beta of -0.21. The business has a 50 day moving average price of $143.56 and a two-hundred day moving average price of $129.97.
Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($1.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.78) by $0.08. Research analysts forecast that Palvella Therapeutics will post -6.29 EPS for the current year.
Insider Buying and Selling
In other Palvella Therapeutics news, Director George M. Jenkins sold 7,174 shares of the firm’s stock in a transaction on Tuesday, October 13th. The stock was sold at an average price of $130.36, for a total transaction of $935,202.64. Following the completion of the sale, the director owned 139,790 shares of the company’s stock, valued at $18,223,024.40. This trade represents a 4.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Kathleen Goin sold 4,313 shares of the business’s stock in a transaction dated Wednesday, October 21st. The shares were sold at an average price of $124.58, for a total transaction of $537,313.54. Following the completion of the sale, the chief operating officer owned 2,165 shares in the company, valued at approximately $269,715.70. This trade represents a 66.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 67,306 shares of company stock valued at $9,800,571 in the last quarter. Corporate insiders own 17.20% of the company’s stock.
Hedge Funds Weigh In On Palvella Therapeutics
Several institutional investors have recently bought and sold shares of PVLA. KBC Group NV acquired a new stake in shares of Palvella Therapeutics in the 1st quarter valued at $28,000. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Palvella Therapeutics during the second quarter worth $35,000. Sterling Capital Management LLC grew its stake in shares of Palvella Therapeutics by 907.7% during the third quarter. Sterling Capital Management LLC now owns 393 shares of the company’s stock worth $54,000 after purchasing an additional 354 shares in the last quarter. Archer Investment Corp purchased a new position in Palvella Therapeutics in the second quarter valued at $69,000. Finally, Quantbot Technologies LP purchased a new position in Palvella Therapeutics in the second quarter valued at $71,000. 40.11% of the stock is owned by institutional investors and hedge funds.
About Palvella Therapeutics
Palvella Therapeutics is a clinical-stage biopharmaceutical company developing treatments for patients with rare and serious diseases, with a focus on conditions affecting the skin and related tissues. The company is based in Wayne, Pennsylvania. Its pipeline includes QTORIN-based topical drug candidates, which use the company’s platform to deliver medicines locally to affected tissue. Programs are being developed for conditions including microcystic lymphatic malformations and cutaneous venous malformations; these candidates are investigational and have not been established as approved treatments.
See Also
- Five stocks we like better than Palvella Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
